PPARG and depressive symptom measurement: GlcCer-PPARγ signaling exerts antidepressant-like effects, which are further enhanced by pioglitazone co-treatment, highlighting a promising therapeutic strategy for depression by targeting GlcCer-PPARγ signaling.